Israël - hébreu - Ministry of Health

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 502.61 mg; dapagliflozin propanediol 12.30 mg - metformin and dapagliflozin

Israël - hébreu - Ministry of Health

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 1005.04 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin

Israël - hébreu - Ministry of Health

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 1005.04 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin

Israël - hébreu - Ministry of Health

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 502.61 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin

Israël - hébreu - Ministry of Health

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 502.61 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin

Israël - hébreu - Ministry of Health

astrazeneca (israel) ltd - budesonide; formoterol fumarate dihydrate; glycopyrronium - תרחיף לשאיפה - formoterol fumarate dihydrate 5 mcg; glycopyrronium 7.2 mcg; budesonide 160 mcg - budesonide

Israël - hébreu - Ministry of Health

astrazeneca (israel) ltd - anifrolumab - תרכיז להכנת תמיסה לאינפוזיה - anifrolumab 150 mg/ml - anifrolumab

Israël - hébreu - Ministry of Health

astrazeneca (israel) ltd - tezepelumab - תמיסה להזרקה - tezepelumab 110 mg/ml - tezepelumab

Israël - hébreu - Ministry of Health

astra zeneca israel ltd - vandetanib 100 mg - film coated tablets - vandetanib - caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (mtc) in patients with unresectable locally advanced or metastatic disease. for patients in whom rearranged during transfection (ret) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision

Israël - hébreu - Ministry of Health

astra zeneca israel ltd - vandetanib 300 mg - film coated tablets - vandetanib - caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (mtc) in patients with unresectable locally advanced or metastatic disease. for patients in whom rearranged during transfection (ret) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision